CGPN-up over 160% on news

[tommyt]

I'm watching, haven't been in pennies for a while, but I 'm a watching.

[setravis]

Up nice, back above the penny.
CandleStick Analysis...looking to be a bullish engulfing.

Technicals
Most Actives
Stochastic - Bullish
Percentage Gainer

Last Price Quote is:
21.55%above 13-day EMA
80.07%above 50-day EMA

[gmarc66]

2005-11-08 08:49:03 
Acquisition of Skystar by Cyber Group Network is Consummated 


XI'AN, China, Nov. 8 /Xinhua-PRNewswire-FirstCall/ -- Cyber Group Network
Corporation, a publicly traded Nevada corporation
(OTC Bulletin Board: CGPN; "CGPN") has successfully closed on the definitive
agreement to acquire Skystar Bio-Pharmaceutical Company Co., Ltd., a Cayman
Islands Company ("Skystar").
The Board of Directors, effective upon Mr. Cramer's resignation as Chief
Executive Officer and Chief Financial Officer on the same day, appointed
Weibing Lu as Chief Executive Officer and a Director, and Erna Gao as Chief
Financial Officer and a Director. The Board of Directors also appointed Wei
Wen and Xinya Zhang as new Directors on the Board.
About Skystar
Skystar is mainly owned by the shareholders of Xian Tianxing
Bio-Pharmaceutical Co., Ltd. (hereafter "Xian Tianxing"), a Chinese company
located in Xi'an China, which was established in July 1997. Skystar has
agreements with Xian Tianxing to manage all of Xian Tianxing's businesses and
to control Xian Tianxing. After 8 years of research and development, Xian
Tianxing is a high-tech bio-pharmaceutical enterprise, engaged in research,
development, and production of bio-pharmaceutical products. Xian Tianxing's
principal products comprise of veterinary drugs, fodder additive,
microorganism preparation products; and it has a veterinary bio-pharmaceutical
research and development center located in Xi'an, China.

[setravis]

Ascending Triangle (continuation) Pattern 

Support @ 0.01
Resistance @ 0.02

Technicals
Percentage Gainer
MACD is Bullish 
Stochastic is Bullish 

Last Price Quote is:
19.32%above 13-day EMA
53.76%above 50-day EMA

Ascending Triangle (Continuation)
The ascending triangle is a bullish formation that usually forms during an uptrend as a continuation pattern. There are instances when ascending triangles form as reversal patterns at the end of a downtrend, but they are typically continuation patterns. Regardless of where they form, ascending triangles are bullish patterns that indicate accumulation

Because of its shape, the pattern can also be referred to as a right-angle triangle. Two or more equal highs form a horizontal line at the top. Two or more rising troughs form an ascending trend line that converges on the horizontal line as it rises. If both lines were extended right, the ascending trend line could act as the hypotenuse of a right triangle. If a perpendicular line were drawn extending down from the left end of the horizontal line, a right triangle would form.

In contrast to the symmetrical triangle, an ascending triangle has a definitive bullish bias before the actual breakout. If you will recall, the symmetrical triangle is a neutral formation that relies on the impending breakout to dictate the direction of the next move. On the ascending triangle, the horizontal line represents overhead supply that prevents the security from moving past a certain level. It is as if a large sell order has been placed at this level and it is taking a number of weeks or months to execute, thus preventing the price from rising further. Even though the price cannot rise past this level, the reaction lows continue to rise. It is these higher lows that indicate increased buying pressure and give the ascending triangle its bullish bias.

[gmarc66]

There was some avian news today that made this stock dance a little, closed up 17% on good volume. Every now and then i notice this stocks bounces around.  Wondering if it will continue tomorrow.

Tuesday, February 14 2006 11:17 AM, EST

Skystar Bio-Pharmaceutical Developing Avian Influenza (H5N1) Vaccine for Humans and Animals

XI'AN, CHINA -- (MARKET WIRE) -- 02/14/06 -- Skystar Bio-Pharmaceutical (OTC BB: CGPN), a leading Bio-Pharmaceutical Company in China, announced that they are developing the highly efficient Avian Influenza Inactivated Vaccine for poultry, birds and humans.

The challenge in making an effective Avian Influenza Vaccine is to solve the issues around the mutation of the actual virus. Once an antigen (vaccine) is introduced to the virus, the virus will mutate rendering the antigen ineffective. For example, a bird or chicken may not show any signs of clinical symptoms after inoculation, but the virus can still hide in its lungs or beak. While hiding, the virus will mutate and become immune to the vaccine. This bird or chicken would now put the rest of the poultry products at risk because it is a "carrier" of a stronger mutated virus.

Skystar is in the process of developing an inactived vaccine. As an inactived vaccine, the Avian Influenza Vaccine merely contains antigen contents but none of the active viral residue, formulated to the latest viral strain. This helps build up immunity in animals and people. This is the same premise in which the annual flu vaccine is based upon.

Current virus technology uses a chicken embryo to breed the virus and produce the vaccine. This technology struggles to keep up with the ever-changing viral strains and is not able to produce enough vaccine to keep up with the demand. Skystar is designing a new technology that is based on a multi-surface cell propagating system. The result is that this process is more controllable and can easily keep up with the virus mutations. Further, this process is more efficient and as a result can be massed produced to keep up with high demand.

Skystar expects to complete their revolutionary vaccine as early as 1st quarter 2007.

About Skystar Bio-Pharmaceutical

Skystar Bio-Pharmaceutical Company, Ltd. (OTC BB: CGPN). Established in 1997, Skystar is a fully GMP certified bio-pharmaceutical company that produces and distributes vaccines, microorganisms and 100% organic herbal additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 60 state-of-the-art products and has over 50 more in the development stage. One of the prominent products in the development stage is a feed additive and vaccine for Avian Influenza. Skystar has formed existing, strategic sales distribution in 27 provinces and regions in China. The State Ministry of Agriculture in China has authorized the additional construction of a new bio-pharmaceutical facility, which will also conform to GMP standards. For more information about Skystar Bio-Pharmaceutical Company, Ltd.'s innovative products and growth plan, please visit http://www.xa-tx.com or contact Scott Cramer [email protected] or (407) 645-4433.